Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells

EuroIntervention

Volumn 7, Issue SUPPL. K, 2011, Pages

  Clever, Yvonne P ^a   Cremers, Bodo ^a   Krauß, Bastian ^a   Böhm, Michael ^a   Speck, Ulrich ^b   Laufs, Ulrich ^a   Scheller, Bruno ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Contrast media; Drug coated balloon; Drug eluting stent; Restenosis

Indexed keywords

IOPROMIDE; PACLITAXEL; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BALLOON; BARE METAL STENT; CELL CULTURE; CELL DENSITY; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SPECIFICITY; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY STENT; DRUG COATED BALLOON; DRUG COATING; DRUG EFFECT; DRUG ELUTING STENT; DRUG FORMULATION; DRUG POTENCY; DRUG SPECIFICITY; ENDOTHELIAL PROGENITOR CELL; HUMAN; HUMAN CELL; NONHUMAN; SMOOTH MUSCLE FIBER; SWINE;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; APOPTOSIS; CARDIOVASCULAR AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; EQUIPMENT DESIGN; HUMANS; IOHEXOL; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PACLITAXEL; SIROLIMUS; STEM CELLS; SUS SCROFA; TIME FACTORS;

EID: 80355139620     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7SKA6     Document Type: Article

References (50)

1. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug eluting stents. Circ J. 2009;73:615-21.
2. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354:483-95. (Pubitemid 43200299)
3. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating - a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810-4. (Pubitemid 39096008)
4. Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Böhm M, Hamm B. Restenosis Inhibition by Non-stent-based Local Drug Delivery: Comparison of Efficacy to a Drug Eluting Stent in the Porcine Coronary Overstretch Model. Radiology. 2006;240:411-8. (Pubitemid 44098636)
5. Dommke C, Haase KK, Süselbeck T, Streitner I, Haghi D, Metz J, Borggrefe M, Herdeg C. Local paclitaxel delivery after coronary stenting in an experimental animal model. Thromb Haemost. 2007;98:674-80. (Pubitemid 47412896)
6. Cremers B, Speck U, Kaufels N, Mahnkopf D, Kühler M, Böhm M, Scheller B: Drug eluting balloon: Very short-term exposure and overlapping. Thromb Haemost. 2009;101:201-6.
7. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of In-stent Restenosis with a Paclitaxelcoated Balloon Catheter. New Engl J Med. 2006;355:2113-24. (Pubitemid 44749319)
8. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Two Year Follow-up after Treatment of Coronary In-stent Restenosis with the Paclitaxel-Coated Balloon Catheter. Clin Res Cardiol. 2008;97:773-81.
9. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-Coated Balloon Catheter versus Paclitaxel-Coated Stent for the Treatment of Coronary In-stent Restenosis. Circulation. 2009;119:2986-2994.
10. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg. New Engl J Med. 2008;358:689-99. (Pubitemid 351240748)
11. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-65.
12. George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A, Michowitz Y, Miller H, Keren G. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol. 2003;23:e57-60.
13. Hristov M, Zernecke A, Liehn EA, Weber C Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost. 2007;98:274-7. (Pubitemid 47250227)
14. Bauters C, Isner JM. The biology of restenosis. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Philadelphia, Pennsylvania: Lippincott-Raven 1998:2465-2490.
15. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-26. (Pubitemid 29054847)
16. Rajagopal V, Rockson SG. Coronary restenosis: a review of mechanisms and management. Am J Med. 2003;115:547-53. (Pubitemid 37352801)
17. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003;9:e17-24.
18. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-88. (Pubitemid 40923403)
19. Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O. Inhibition of Restenosis in Stented Porcine Coronary Arteries: Uptake of Paclitaxel from Angiographic Contrast Media. Invest Ra-diol. 2004;39:182-6. (Pubitemid 38263924)
20. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007. (Pubitemid 41262334)
21. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jürgens K, Miche E, Böhm M, Nickenig G. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004 Jan 20;109:220-6. Epub Dec 22.
22. Gensch C, Clever YP, Werner C, Hanhoun M, Böhm M, Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis. 2007;192:67-74. (Pubitemid 46628806)
23. Wessely R, Blaich B, Belaiba RS, Merl S, Görlach A, Kastrati A, Schömig A. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost. 2007;97:1003-12. (Pubitemid 46939215)
24. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation. 1992;86:723-9.
25. Hristov M, Weber C. Progenitor cell trafficking in the vascular wall. J Thromb Haemost. 2009;7 Suppl 1:31-4.
26. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008 Oct;8(10):802-15.
27. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-7.
28. Luo Y, Marx SO, Kiyokawa H, Koff A, Massagué J, Marks AR. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol. 1996;16:6744-51. (Pubitemid 26389733)
29. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-83. (Pubitemid 26394201)
30. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration. Circulation. 2001;103:2967-72. (Pubitemid 32578136)
31. Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J. Drug eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol. 2005;524:19-29. (Pubitemid 41606808)
32. Wilson L, Bamburg JR, Mizel SB, Grisham LM, Creswell KM. Interaction of drugs with microtubule proteins. Fed Proc. 1974;33:158-166.
33. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther. 1984;25:83-125. (Pubitemid 14035723)
34. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature. 1979;277:665-667. (Pubitemid 9114288)
35. Wang TH, Wang HS Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88:2619-28.
36. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999;17:1061-70. (Pubitemid 29109340)
37. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3:193-203. (Pubitemid 36565761)
38. Fan S, Cherney B, Reinhold W, Rucker K, O'Connor PM. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res. 1998;4:1047-54. (Pubitemid 28183408)
39. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001;20:3806-13. (Pubitemid 32646191)
40. Shu CH, Yang WK, Shih YL, Kuo ML, Huang TS. Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with lowdose paclitaxel-induced sub-G1 apoptosis. Apoptosis. 1997;2:463-70. (Pubitemid 127508257)
41. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, Wild DH, Brehm BR, Riessen R, Köveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-45. (Pubitemid 27329445)
42. Blagosklonny Darzynkiewicz Z, Halicka HD, Pozarowski P, Demidenko ZN, Barry JJ, Kamath KR, Herrmann RA. Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle. 2004;3:1050-6. (Pubitemid 40268664)
43. Blagosklonny MV, Demidenko ZN, Giovino M, Szynal C, Donskoy E, Herrmann RA, Barry JJ, Whalen AM. Cytostatic activity of paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest: comparison with cancer cells. Cell Cycle. 2006;5:1574-9. (Pubitemid 44091979)
44. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug eluting-stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;26:326-332.
45. Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42:1415-20. (Pubitemid 37267283)
46. Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M, Stoll HP. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J. 2003;24:1462-7. (Pubitemid 36961837)
47. Scheller B, Speck U, Böhm M. Prevention of Restenosis - is Angioplasty the Answer? Heart. 2007;93:539-41.
48. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug eluting stents. N Engl J Med. 2007;356:1020-9. (Pubitemid 46376802)
49. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P. Role of endothelium in modulating neointimal formation. Vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 2004;44:733-9. (Pubitemid 39099565)
50. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res. 2006;98:e20-5.